 |
Solebury Trout is working with the investment community for Novavax, which has announced its COVID-19 vaccine has a 93 percent efficacy rate against the virus.
Stanley Erck, CEO of the Gaithersburg, MD biotech, said Novavax “is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines."
The firm plans to file for regulatory approval for its NVX-CoV2373 vaccine in the third quarter.
Once approved, Novavax said it will be able to produce 100M shots a month by the end of Q3 and 150 doses by year-end.
Novavax, which is 33 years old, has never had a vaccine approved by the Food and Drug Administration.
Solebury Trout’s Alexandria Roy represents Novavax.
FGS Global represents private equity firm Thoma Bravo as it makes a $4.6B bid for Darktrace, a UK-based cybersecurity artificial intelligence firm.
Edelman handles Viking Holdings, the river and ocean luxury cruise line that plans to raise $1B via an IPO priced in the $21 to $25 per share range.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Have a comment? Send it to 
No comments have been submitted for this story yet.